未登录

G

G. Christopher Wood

University of Tennessee

H指数:37

被引数:5,110

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

960: PRE/POST EVALUATION OF A VTE PROPHYLAXIS PATHWAY WITH WEIGHT-BASED DOSING AT A LEVEL 1 TRAUMA CENTER

960: 对一所一级创伤中心采用基于体重剂量的VTE预防路径的预/后评估

Critical Care Medicine

IF6

2026-03-030

PRE

IMPACT OF PSEUDOEPHEDRINE AND/OR MIDODRINE ON NEUROGENIC SHOCK FOLLOWING ACUTE SPINAL CORD INJURY

伪麻黄碱和/或米多君对急性脊髓损伤后神经源性休克的影响

CRITICAL CARE MEDICINE

IF6

2025-01-300

PRE

EFFECT OF PROPRANOLOL ON HYPERPYREXIA IN PATIENTS WITH TBI AND PAROXYSMAL SYMPATHETIC HYPERACTIVITY

普萘洛尔对TBI合并阵发性交感神经过度活跃患者高热的影响

CRITICAL CARE MEDICINE

IF6

2025-01-300

PRE

INCIDENCE OF MULTIDRUG-RESISTANT VAP PATHOGENS IN THREE GEOGRAPHICALLY DISTINCT TRAUMA UNITS

三所地理位置不同的创伤病房中多重耐药VAP病原体的发病率

CRITICAL CARE MEDICINE

IF6

2023-12-140

OA

Osteoarthritis in people over 16: diagnosis and management-updated summary of NICE guidance

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2023-01-2427

PRE

COVID-19 COMPLICATED BY THE INVASION OF ASPERGILLUS TERREUS

IF8.6

2021-10-010

OAAI

Lyophilized Iron Oxide Nanoparticles Encapsulated in Amphotericin B: A Novel Targeted Nano Drug Delivery System for the Treatment of Systemic Fungal Infections

IF5.5

2020-03-1016

OAAI

Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial

LANCET INFECTIOUS DISEASES

IF31

2020-03-0194

PREAI

THE ALBERTA 2016-2020 STBBI OPERATIONAL STRATEGY AND ACTION PLAN: COLLECTIVE IMPACT TO ADDRESS THE PROVINCIAL STI OUTBREAK

SEXUALLY TRANSMITTED INFECTIONS

IF2.9

2019-07-140

PREAI

Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies

IF5.5

2018-04-156

OAAI

Nebulization of Cyclic Arginine-Glycine-(D)-Aspartic Acid-Peptide Grafted and Drug Encapsulated Liposomes for Inhibition of Acute Lung Injury

PHARMACEUTICAL RESEARCH

IF4.3

2018-03-139

PREAI

Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2016-01-01146

PREAI

Short-duration treatment for catheter-associated urinary tract infections in critically ill trauma patients

危重创伤患者导管相关性尿路感染的短期治疗

JOURNAL OF TRAUMA AND ACUTE CARE SURGERY

IF3.7

2015-10-0110

PREAI

Impact of Pathogen-Directed Antimicrobial Therapy for Ventilator-Associated Pneumonia in Trauma Patients on Charges and Recurrence

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

IF3.4

2015-04-0110

PREAI

Adherence to an established diagnostic threshold for ventilator-associated pneumonia contributes to low false-negative rates in trauma patients

JOURNAL OF TRAUMA AND ACUTE CARE SURGERY

IF3.7

2015-03-0113

PREAI

Optimization of drug loading to improve physical stability of paclitaxel-loaded long-circulating liposomes

JOURNAL OF LIPOSOME RESEARCH

IF4.3

2014-12-2628

PREAI

Effect of sucrose as a lyoprotectant on the integrity of paclitaxel-loaded liposomes during lyophilization

JOURNAL OF LIPOSOME RESEARCH

IF4.3

2014-12-2341

PREAI

Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY

IF3.8

2014-01-1037

PREAI

Short Duration Treatment for Catheter-Associated Urinary Tract Infection in Trauma ICU Patients

CRITICAL CARE MEDICINE

IF6

2013-12-010

PREAI

Treatment of Achromobacter Ventilator-Associated Pneumonia in Critically Ill Trauma Patients

CRITICAL CARE MEDICINE

IF6

2013-12-010

PREAI